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Hypoxic and VHL-deficient cells use glutamine to
generate citrate and lipids through reductive carbox-
ylation (RC) of a-ketoglutarate. To gain insights into
the role of HIF and themolecular mechanisms under-
lying RC, we took advantage of a panel of disease-
associated VHL mutants and showed that HIF
expression is necessary and sufficient for the induc-
tion of RC in human renal cell carcinoma (RCC) cells.
HIF expression drastically reduced intracellular
citrate levels. Feeding VHL-deficient RCC cells with
acetate or citrate or knocking down PDK-1 and
ACLY restored citrate levels and suppressed RC.
These data suggest that HIF-induced low intra-
cellular citrate levels promote the reductive flux by
mass action to maintain lipogenesis. Using [1–13C]
glutamine, we demonstrated in vivo RC activity
in VHL-deficient tumors growing as xenografts in
mice. Lastly, HIF rendered VHL-deficient cells sensi-
tive to glutamine deprivation in vitro, and systemic
administration of glutaminase inhibitors suppressed
the growth of RCC cells as mice xenografts.
INTRODUCTION
Cancer cells undergo fundamental changes in their metabolism
to support rapid growth, adapt to limited nutrient resources,
and compete for these supplies with surrounding normal cells.
One of the metabolic hallmarks of cancer is the activation
of glycolysis and lactate production even in the presence of
adequate oxygen. This is termed the Warburg effect, and efforts
in cancer biology have revealed some of the molecular mecha-
nisms responsible for this phenotype (Cairns et al., 2011). More
recently, 13C isotopic studies have elucidated the complemen-
tary switch of glutamine metabolism that supports efficient372 Cell Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc.carbon utilization for anabolism and growth (DeBerardinis and
Cheng, 2010). Acetyl-CoA is a central biosynthetic precursor
for lipid synthesis, being generated from glucose-derived citrate
in well-oxygenated cells (Hatzivassiliou et al., 2005). Warburg-
like cells, and those exposed to hypoxia, divert glucose to
lactate, raising the question of how the tricarboxylic acid (TCA)
cycle is supplied with acetyl-CoA to support lipogenesis. We
and others demonstrated, using 13C isotopic tracers, that cells
under hypoxic conditions or defective mitochondria primarily
utilize glutamine to generate citrate and lipids through reduc-
tive carboxylation (RC) of a-ketoglutarate by isocitrate dehydro-
genase 1 (IDH1) or 2 (IDH2) (Filipp et al., 2012; Metallo et al.,
2012; Mullen et al., 2012; Wise et al., 2011).
The transcription factors hypoxia inducible factors 1a and 2a
(HIF-1a, HIF-2a) have been established as master regulators of
the hypoxic program and tumor phenotype (Gordan and Simon,
2007; Semenza, 2010). In addition to tumor-associated hypoxia,
HIF can be directly activated by cancer-associated mutations.
The von Hippel-Lindau (VHL) tumor suppressor is inactivated in
the majority of sporadic clear-cell renal carcinomas (RCC), with
VHL-deficient RCC cells exhibiting constitutive HIF-1a and/or
HIF-2a activity irrespective of oxygen availability (Kim and
Kaelin, 2003). Previously, we showed that VHL-deficient cells
also relied on RC for lipid synthesis even under normoxia.
Moreover, metabolic profiling of two isogenic clones that differ
in pVHL expression (WT8 and PRC3) suggested that reintroduc-
tion of wild-type VHL can restore glucose utilization for lipogen-
esis (Metallo et al., 2012). The VHL tumor suppressor protein
(pVHL) has been reported to have several functions other than
the well-studied targeting of HIF. Specifically, it has been re-
ported that pVHL regulates the large subunit of RNA polymerase
(Pol) II (Mikhaylova et al., 2008), p53 (Roe et al., 2006), and the
Wnt signaling regulator Jade-1. VHL has also been implicated
in regulation of NF-kB signaling, tubulin polymerization, cilia
biogenesis, and proper assembly of extracellular fibronectin
(Chitalia et al., 2008; Kim and Kaelin, 2003; Ohh et al., 1998;
Thoma et al., 2007; Yang et al., 2007). Hypoxia inactivates the
a-ketoglutarate-dependent HIF prolyl hydroxylases, leading to
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HIF Promotes Reductive TCA Cycle and Gln Addictionstabilization of HIF. In addition to this well-established function,
oxygen tension regulates a larger family of a-ketoglutarate-
dependent cellular oxygenases, leading to posttranslational
modification of several substrates, among which are chromatin
modifiers (Melvin and Rocha, 2012). It is therefore conceivable
that the effect of hypoxia on RC that was reported previously
may be mediated by signaling mechanisms independent of the
disruption of the pVHL-HIF interaction. Here we (1) demonstrate
that HIF is necessary and sufficient for RC, (2) provide insights
into the molecular mechanisms that link HIF to RC, (3) detected
RC activity in vivo in human VHL-deficient RCC cells growing
as tumors in nude mice, (4) provide evidence that the reductive
phenotype of VHL-deficient cells renders them sensitive to
glutamine restriction in vitro, and (5) show that inhibition of gluta-
minase suppresses growth of VHL-deficient cells in nude mice.
These observations lay the ground for metabolism-based thera-
peutic strategies for targeting HIF-driven tumors (such as RCC)
andpossibly the hypoxic compartment of solid tumors in general.
RESULTS
Functional Interaction between pVHL and HIF
Is Necessary to Inhibit RC
To test whether the inhibition of RC by pVHL requires its ability to
bind and inactivate the alpha regulatory subunit of HIF, we tested
a panel of VHL germline mutations that are linked to different
clinical phenotypes of the VHL disease and differ in their affinity
to bind HIF. Missense germline type 2A VHL mutations confer
a low risk for RCC to their carrier individuals and retain an atten-
uated HIF binding and regulatory activity. In contrast, type 2B
mutations, which are defective in HIF binding and regulation,
confer a high risk for RCC. On the other hand, type 2C VHL germ-
line mutations are associated with an increased risk of pheo-
chromocytomas, but not RCC, and they retain the ability to
bind and inactivate HIF in a manner similar to wild-type protein,
an observation that suggests that type 2C mutations inactivate
HIF-independent function(s) of pVHL (Li et al., 2007).
We infected VHL-deficient human UMRC2 renal carcinoma
cells with retroviruses and generated polyclonal cell populations
expressing wild-type pVHL or type 2A (Y112H), type 2B (Y98N,
Y112N), and type 2C (L188V) pVHL mutants. First, we confirmed
that expression of HIF-1a/HIF-2a and their downstream target
GLUT1 were downregulated in cells expressing wild-type pVHL
or type 2C mutant protein (Figure 1A). The effect of type 2A
pVHL mutations appeared intermediate between wild-type and
type 2B mutations regarding GLUT1 (Figure 1A, GLUT1 lane).
To profile the metabolic phenotype of the engineered
cell lines, we labeled the cells with either [U13-C6]glucose or
[1-13C1]glutamine and determined the incorporation of each
tracer in TCA cycle metabolites using gas chromatography-
mass spectrometry (GC-MS) (Figure 1B). Reintroduction of
wild-type pVHL or type 2C pVHL mutant suppressed the contri-
bution of reductive carboxylation from glutamine (Figure 1C), as
determined by the degree of labeled carbon (M1 enrichment) of
the indicated metabolites (see Figure 1B, green circles).
Conversely, type 2B mutants (Y112N/Y98N, which are defective
in HIF inactivation) exhibited active RC to a level comparable to
VHL-deficient control cells.We observed a concurrent regulation
in glucose metabolism in the different VHLmutants. Reintroduc-Cetion of wild-type or type 2C pVHL mutant, which can meditate
HIF-a destruction, stimulated glucose oxidation via pyruvate
dehydrogenase (PDH), as determined by the degree of
13C-labeled TCA cycle metabolites (M2 enrichment) (Figures
1D and 1E). In contrast, reintroduction of an HIF nonbinding
Type 2B pVHL mutant failed to stimulate glucose oxidation,
resembling the phenotype observed in VHL-deficient cells
(Figures 1D and 1E). Additional evidence for the overall glucose
utilization was obtained from the enrichment of M3 isotopomers
using [U13-C6]glucose (Figure S1A), which shows a lower contri-
bution of glucose-derived carbons to the TCA cycle in VHL-
deficient RCC cells (via pyruvate carboxylase and/or continued
TCA cycling).
To test the effect of HIF activation on the overall glutamine
incorporation in the TCA cycle, we labeled an isogenic pair
of VHL-deficient and VHL-reconstituted UMRC2 cells with
[U-13C5]glutamine, which generates M4 fumarate, M4 malate,
M4 aspartate, and M4 citrate isotopomers through glutamine
oxidation. As seen in Figure S1B, VHL-deficient/VHL-positive
UMRC2 cells exhibit similar enrichment of M4 fumarate, M4
malate, and M4 asparate (but not citrate) showing that VHL-
deficient cells upregulate reductive carboxylation without
compromising oxidative metabolism from glutamine. Next, we
tested whether HIF inactivation by pVHL is necessary to regulate
the reductive utilization of glutamine for lipogenesis. To this end,
we traced the relative incorporation of [U-13C6]glucose or
[5-13C1]glutamine into palmitate. Labeled carbon derived from
[5-13C1]glutamine can be incorporated into fatty acids exclu-
sively through RC, and the labeled carbon cannot be transferred
to palmitate through the oxidative TCA cycle (Figure 1B, red
carbons). Tracer incorporation from [5-13C1]glutamine occurs
in the one carbon (C1) of acetyl-CoA, which results in labeling
of palmitate at M1, M2, M3, M4, M5, M6, M7, and M8 mass iso-
topomers. In contrast, lipogenic acetyl-CoA molecules origi-
nating from [U-13C6]glucose are fully labeled, and the labeled
palmitate is represented by M2, M4, M6, M8, M10, M12, M14,
and M16 mass isotopomers. VHL-deficient control cells and
cells expressing pVHL type 2B mutants exhibited high palmitate
labeling from the [5-13C1]glutamine; conversely, reintroduction
of wild-type or type 2C pVHL mutant (L188V) resulted in high
labeling from [U-13C6]glucose (Figures 2A and 2B, box inserts
highlight the heavier mass isotopomers).
Next, to determine the specific contribution from glucose
oxidation or glutamine reduction to lipogenic acetyl-CoA,weper-
formed isotopomer spectral analysis (ISA) of palmitate labeling
patterns. ISA indicates that wild-type pVHL or pVHL L188V
mutant-reconstituted UMRC2 cells relied mainly on glucose
oxidation to produce lipogenic acetyl-CoA, while UMRC2 cells
reconstituted with a pVHL mutant defective in HIF inactivation
(Y112N or Y98N) primarily employed RC. Upon disruption of
the pVHL-HIF interaction, glutamine becomes the preferred
substrate for lipogenesis, supplying 70%–80% of the lipogenic
acetyl-CoA (Figure 2C). This is not a cell-line-specific phenom-
enon, but it applies to VHL-deficient human RCC cells in general;
the same changes are observed in 786-O cells reconstituted with
wild-type pVHL or mutant pVHL or infected with vector only as
control (Figure S2). Type 2A pVHL mutants (Y112H, which retain
partial HIF binding) confer an intermediate reductive phenotype
between wild-type VHL (which inactivates HIF) and type 2Bll Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc. 373
Figure 1. HIF Inactivation Is Necessary for Downregulation of Reductive Carboxylation by pVHL
(A) Expression of HIF-1 a, HIF-2a, and their target protein GLUT1 in UMRC2-derived cell lines, as indicated.
(B) Carbon atom transition map: the fate of [1-13C1] and [5-
13C1]glutamine used to trace reductive carboxylation in this work (carbon atoms are represented by
circles). The [1-13C1] (green circle) and [5-
13C1] (red circle) glutamine-derived isotopic labels are retained during the reductive TCA cycle (bold red pathway).
Metabolites containing the acetyl-CoA carbon skeleton are highlighted by dashed circles.
(C) Relative contribution of reductive carboxylation.
(D and E) Relative contribution of glucose oxidation to the carbons of indicated metabolites (D) and citrate (E). Student’s t test compared VHL-reconstituted to
vector-only or to VHL mutants (Y98N/Y112N). Error bars represent SEM. Pyr, pyruvate; Lac, lactate; AcCoA, acetyl-CoA, Cit, citrate; IsoCit, isocitrate; Akg,
a-ketoglutarate; Suc, succinate; Fum, fumarate; Mal, malate; OAA, oxaloacetate; Asp, aspartate; Glu, glutamate; PDH, pyruvate dehydrogenase; ME, malic
enzyme; IDH, isocitrate dehydrogenase enzymes; ACO, aconitase enzymes; ACLY, ATP-citrate lyase; GLS, glutaminase. See also Figure S1.
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seen in Figures 1 and 2. Taken together, these data demonstrate
that the ability of pVHL to regulate reductive carboxylation and
lipogenesis from glutamine tracks genetically with its ability to
bind and degrade HIF, at least in RCC cells.374 Cell Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc.HIF Is Sufficient to Induce RC from Glutamine in RCC
Cells
To test the hypothesis that HIF-2a is sufficient to promote
RC from glutamine, we expressed a pVHL-insensitive HIF-2a
mutant (HIF-2a P405A/P531A, marked as HIF-2a P-A) in
Figure 2. HIF Inactivation Is Necessary for Downregulation of Reductive Lipogenesis by pVHL
(A and B) VHL-deficient UMRC2 cells were cultured for 3 days in the presence of either [U-13C6]glucose or [5-
13C1]glutamine. Mass isotopomer distributions
(MIDs) of biomass-extracted palmitate in parental cells reconstituted with empty vector control (vector), wild-type EE-VHL, or HA-VHL mutants and labeled with
[5-13C1]glutamine (A) or [U-
13C6]glucose (B). Note: M0 equals 70%–80%; scale shown up to 20%. Error bars represent SEM.
(C) Specific contribution to lipogenic acetyl-CoA as estimated by the ISA method. Error bars represent 95% confidence intervals. See also Figure S2.
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HIF Promotes Reductive TCA Cycle and Gln AddictionVHL-reconstituted 786-O cells (Figure 3). HIF-2a P-A is con-
stitutively expressed in this polyclonal cell population, despite
the reintroduction of wild-type VHL, reflecting a pseudohypoxia
condition (Figure 3A). We confirmed that this mutant is transcrip-
tionally active by assaying for the expression of its targets
genes GLUT1, LDHA, HK1, EGLN, HIG2, and VEGF (Figures
3B and S3A). As shown in Figure 3C, reintroduction of wild-
type VHL into 786-O cells suppressed RC, whereas the expres-
sion of the constitutively active HIF-2a mutant was sufficient
to stimulate this reaction, restoring the M1 enrichment of TCA
cycle metabolites observed in VHL-deficient 786-O cells.
Expression of HIF-2a P-A also led to a concomitant decrease
in glucose oxidation, corroborating the metabolic alterations
observed in glutamine metabolism (Figures 3D and 3E). Addi-
tional evidence of the HIF2a-regulation on the reductive
phenotype was obtained with [U-13C5]glutamine, which gener-
ates M5 citrate, M3 fumarate, M3 malate, and M3 aspartate
through RC (Figure 3F).
Next, we tested whether VHL-independent HIF-2a expression
was sufficient not only to stimulate RC in the TCA cycle but alsoCeto switch the substrate preference for lipogenesis from glucose
to glutamine. Expression of HIF-2aP-A in 786-O cells phenocop-
ied the loss-of-VHL with regards to glutamine reduction for lipo-
genesis (Figure 3G), suggesting that HIF-2a can induce the
glutamine-to-lipid pathway in RCC cells per se. Although reintro-
duction of wild-type VHL restored glucose oxidation in UMRC2
and UMRC3 cells (Figures S3B–S3I), HIF-2a P-A expression
did not measurably affect the contribution of each substrate to
the TCA cycle or lipid synthesis in these RCC cells (data not
shown). UMRC2 and UMRC3 cells endogenously express both
HIF-1a and HIF-2a, whereas 786-O cells exclusively express
HIF-2a. There is compelling evidence suggesting, at least in
RCC cells, that HIF-a isoforms have overlapping—but also
distinct—functions and their roles in regulating bioenergetic
processes remain an area of active investigation. Overall,
HIF-1a has an antiproliferative effect, and its expression in vitro
leads to rapid death of RCC cells while HIF-2a promotes tumor
growth (Keith et al., 2011; Raval et al., 2005). Because of this,
wewere not able to stably express the HIF-1aP-Amutant in cells
that endogenously express HIF-2a only. To get insights into thell Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc. 375
Figure 3. Expression of HIF-2a Is Sufficient to Induce Reductive Carboxylation and Lipogenesis from Glutamine in RCC Cells
(A) Schematic of stabilized HIF-2a expression under normoxia conditions.
(B) Expression of pVHL, HIF-2a, and its target protein GLUT1 in 786-O-derived cells, as indicated.
(C) Relative contribution of reductive carboxylation.
(D and E) Relative contribution of glucose oxidation to the carbons of indicated metabolites (D) and citrate (E).
(F) Evidence for induction of reductive carboxylation by HIF-2a P-A using [U-13C5]glutamine. Student’s t test compared VHL-reconstituted or mutant
HIF-2a-expressing cells to corresponding controls. Error bars represent SEM.
(G) ISA results showing the specific contribution of glucose oxidation and glutamine reduction to lipogenic acetyl-CoA (error bars denote 95% confidence
intervals). See also Figure S3.
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epithelial kidney (NEK) cells and selectively induced the expres-
sion of mouse HIF-1a or HIF-2a P-A in normoxia. Expressing
HIF-1a P-A activated RC, consistent with our observation in
cancer cell lines. In this model, HIF-2a P-A did not affect the
contribution of this reaction to any of the TCA cycle metabolites,
at least in the condition studied (Figure S3J). Thus, it is possible
that the induction of RC by HIF-1a or HIF-2a is species- or cell-376 Cell Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc.type-specific. Alternatively, there may be a redundant role of the
paralogs, and/or one may adapt the control of the metabolic
program in the absence of the other paralog.
Metabolic Flux Analysis Shows Net Reversion of the IDH
Flux upon HIF Activation
To determine absolute fluxes in RCC cells, we employed
13C metabolic flux analysis (MFA) as previously described
Figure 4. Metabolic Flux Analysis of VHL-Deficient and VHL-Positive Cells
(A) Extracellular fluxes (Glc and Gln uptake, Glu and lactic acid secretion) in PRC3 (VHL/) and WT8 (VHL+) isogenic cells. Error bars denote SEM.
(B) Net influx of glutamine-derived carbons determined by the difference between glutamine uptake and glutamate secretion. Error bars denote SEM.
(C) Flux estimates from combined [U-13C6]glucose/[1-
13C1]glutamine MFA model. Student’s t test compared WT8 to PRC3 cells. GDH, glutamate dehydroge-
nase; AAT, aspartate aminotransferase; PDH, pyruvate dehydrogenase; CS, citrate synthase; IDH, isocitrate dehydrogenase; ACO, aconitase; MDH, malate
dehydrogenase; ACLY, ATP-citrate lyase; Pyr transp, pyruvate transport between cytosol and mitochondria. Error bars denote 95% confidence intervals.
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a combined model of [U-13C6]glucose and [1-
13C1]glutamine
tracer data sets from the 786-O derived isogenic clones PRC3
(VHL/)/WT8 (VHL+) cells, which show a robust metabolic regu-
lation by reintroduction of pVHL. To this end, we first determined
specific glucose/glutamine consumption and lactate/glutamate
secretion rates. As expected, PRC3 exhibited increased glucose
consumption and lactate production when compared to WT8
counterparts (Figure 4A). While PRC3 exhibited both higher
glutamine consumption and glutamate production rates than
WT8 (Figure 4A), the net carbon influx was higher in PRC3 cells
(Figure 4B). Importantly, the fitted data show that the flux of
citrate to a-ketoglutarate was negative in PRC3 cells (Figure 4C).
This indicates that the net (forward plus reverse) flux of isocitrate
dehydrogenase and aconitase (IDH + ACO) is toward citrate
production. The exchange flux was also higher in PRC3 than
WT8 cells, whereas the PDH flux was lower in PRC3 cells. InCeagreement with the tracer data, these MFA results strongly
suggest that the reverse IDH + ACO fluxes surpass the forward
flux in VHL-deficient cells. The estimated ATP citrate lyase
(ACLY) flux was also lower in PRC3 than in WT8 cells. Further-
more, the malate dehydrogenase (MDH) flux was negative,
reflecting a net conversion of oxaloacetate into malate in VHL-
deficient cells (Figure 4C). This indicates an increased flux
through the reductive pathway downstream of IDH, ACO, and
ACLY. Additionally, some TCA cycle flux estimates downstream
of a-ketoglutarate were not significantly different between PRC
andWT8 (Table S1). This shows thatVHL-deficient cellsmaintain
glutamine oxidation while upregulating reductive carboxylation
(Figure S1B). This finding is in agreement with the higher gluta-
mine uptake observed in VHL-deficient cells. Table S1 shows
the metabolic network and complete MFA results. Similar MFA
results were obtained in VHL-deficient vector versus VHL-recon-
stituted UMRC2 cells (data not shown). Together, the MFA datall Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc. 377
Figure 5. Regulation of HIF-Mediated Reductive Carboxylation by Citrate Levels
(A and B) Citrate ion counts (A) and citrate-to-a-ketoglutarate ratio (B) in RCC cells. Student’s t test compared VHL-reconstituted to VHL-deficient cells.
(C) Validation of PDK-1 knockdown in VHL-deficient PRC3 cells.
(D) Relative contribution of reductive carboxylation to the TCA cycle under PDK-1 knockdown conditions. Student’s t test compared PDK-1 knockdown to
control cells.
(E) Validation of ACLY knockdown in PRC3 cells.
(F) Effect of ACLY knockdown on the relative contribution of reductive carboxylation. Student’s t test compared ACLY knockdown to control cells.
(G and H) Effect of acetate and citrate on the activity of reductive carboxylation in VHL-deficient/VHL-reconstituted UMRC2 cells. Acetate suppresses the relative
(G) and total (H) contribution of reductive carboxylation in VHL-deficient UMRC2 cells.
(legend continued on next page)
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compensate for a deficient citrate production due to inhibition
of PDH.
HIF Activation Promotes RC by Lowering Citrate Levels
In support of the existing literature, our MFA data showed that
HIF inhibits the absolute pyruvate dehydrogenase (PDH) flux
(Kim et al., 2006; Papandreou et al., 2006). We observed that
citrate levels were depleted in VHL-deficient UMRC2 cells (Fig-
ure 5A), with the citrate-to-a-ketoglutarate ratio being equally
decreased in the VHL-deficient and HIF-2a P-A-expressing
RCC cell lines (Figures 5B and S4A). We hypothesized that
low citrate levels are key in promoting RC through mass action.
To test if the mechanism by which HIF promotes RC lies in its
ability to reduce citrate levels, we restored the intracellular pools
of citrate, hoping to suppress RC in the TCA cycle. First, we
knocked down the HIF target PDK-1 (Figure 5C) and observed
a decreased contribution of RC to the TCA cycle in VHL-
deficient PRC3 cells (Figure 5D). Similarly, knocking down the
ATP citrate lyase enzyme (Figure 5E) inhibited RC in PRC3 cells
(relative contribution of RC in Figure 5F, total contribution of RC
in Figure S4B). Next, we labeled VHL-deficient and VHL-recon-
stituted UMRC2 cells with [1-13C1]glutamine and supplemented
the medium with 1 mM and 4 mM acetate. Addition of acetate
decreased the relative (Figure 5G) and total contribution (Fig-
ure 5H) of RC in VHL-deficient cells, with minimal effects
observed in the VHL-reconstituted counterparts. The M1
enrichment informs on RC for the formation of TCA cycle
metabolites. The absence of a major effect of acetate on the
minimal RC of VHL-reconstituted cells is consistent with the
observation that addition of acetate to these cells did not
increase the intracellular citrate levels significantly (Figures 5I
and S4C). In contrast, addition of acetate to VHL-deficient cells
led to a significant increase in their citrate levels (Figures 5I and
S4C) (to a level similar to the one observed in VHL-positive cells)
as well as significant inhibition of RC. To pinpoint the metabolic
route of the acetate-to-citrate flux, we labeled the control and
ACLY knockdown PRC3 cells with [U-13C2]acetate and ob-
served an increased percentage of M2 citrate under ACLY
knockdown conditions (Figure S4D), suggesting that the acetate
rescue of citrate levels in VHL-deficient cells probably occurs
through condensation with oxaloacetate via citrate synthase
rather than through the reversibility of ACLY. We confirmed
that acetate can serve as a lipogenic source in the pair of
PRC3/WT8 cells (Figure S4E). We also cultured PRC3/WT8 cells
with [5-13C1]glutamine in the presence of naturally labeled
acetate. In line with the previous observations, the contribution
of glutamine reduction to lipogenic acetyl-CoA was decreased
under the presence of acetate (Figure S4F). Next, we directly
supplemented the medium with citrate and rinsed the cells thor-
oughly with PBS before extraction to ensure measurement of
the intracellular metabolite. Addition of 8 mM citrate decreased
the M1 enrichment of citrate in VHL-deficient UMRC2 cells to
half but, in contrast to acetate, did have a moderate effect on(I) Rescue of citrate-to-a-ketoglutarate ratio by acetate addition.
(J and K) Exogenous citrate suppresses the relative (J) and total (K) contribution
(L) Rescue of citrate-to-a-ketoglutarate ratio by exogenous citrate in (K). AC
denote SEM. See also Figure S4.
Cethe minimal RC observed in VHL-reconstituted cells (Figure 5J).
Interestingly the level of M1 fumarate, M1 aspartate, and M1
malate were unaffected. One could expect the addition of
nonlabeled citrate to decrease, by definition, the percent enrich-
ment of M1 citrate, regardless of its putative effect on RC. To
control for this effect of exogenous citrate on the total
formation of RC-derived citrate, we labeled the cells with
[1-13C1]glutamine and [U-
13C6]citrate and subtracted the total
M6 citrate ions (which are exogenous and not metabolically
generated by the cell) from the total citrate ions and calculated
the total contribution of RC using the formula % M1 3 (total
ions% M6 3 total ions). Likewise, exogenous citrate signifi-
cantly decreased the total contribution of RC in the VHL-
deficient UMRC2 cells but also had a moderate effect in the
RC observed in VHL-reconstituted cells (Figure 5K). This differ-
ential effect between acetate and citrate on RC is consistent
with and supports our hypothesis that endogenous citrate levels
regulate RC by mass action. Addition of citrate in the medium,
in contrast to acetate, led to an increase in the citrate-to-
a-ketoglutarate ratio (Figure 5L) and absolute citrate levels (Fig-
ure S4H) not only in VHL-deficient but also VHL-reconstituted
cells. The ability of exogenous citrate, but not acetate, to also
affect RC in VHL-reconstituted cells may be explained by
compartmentalization differences or by allosteric inhibition of
citrate synthase (Lehninger, 2005); that is, the ability of acetate
to raise the intracellular levels of citrate may be limited in (VHL-
reconstituted) cells that exhibit high endogenous levels of citrate.
Whatever the mechanism, the results imply that increasing the
pools of intracellular citrate has a direct biochemical effect in
cells with regards to their reliance on RC. Finally, we assayed
the transcript and protein levels of enzymes involved in the
reductive utilization of glutamine and did not observe signifi-
cant differences between VHL-deficient and VHL-reconstituted
UMRC2 cells (Figures S4I and S4J), suggesting that HIF does
not promote RC by direct transactivation of these enzymes.
The IDH1/IDH2 equilibrium is defined as follows:
½a ketoglutarate½NADPH½CO2
½Isocitrate½NADP+  =KðIDHÞ
Therefore, we sought to investigate whether HIF could affect
the driving force of the IDH reaction by also enhancing NADPH
production. We did not observe a significant alteration of the
NADP+/NADPH ratio between VHL-deficient and VHL-positive
cells in the cell lysate (Figure S4I). Yet, we determined the ratio
of the free dinucleotides using the measured ratios of suitable
oxidized (a-ketoglutarate) and reduced (isocitrate/citrate)
metabolites that are linked to the NADP-dependent IDH
enzymes. The determined ratios (Figure S4J) are in close agree-
ment with the values initially reported by the Krebs lab (Veech
et al., 1969) and showed that HIF-expressing UMRC2 cells
exhibit a higher NADP+/NADPH ratio. Collectively, these data
strongly suggest that HIF-regulated citrate levels modulate the
reductive flux to maintain adequate lipogenesis.of reductive carboxylation in VHL-deficient UMRC2 cells.
LY, ATP-citrate lyase; PDK-1, pyruvate dehydrogenase kinase. Error bars
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Figure 6. Evidence for Reductive Carboxylation Activity In Vivo
(A) Time course of 13C enrichment (%) of glutamine in tumor, normal kidney, and plasma extracts during infusion with [1-13C1]glutamine.
13C enrichment at time
zero was determined using control noninfused mice.
(B) Percent M1 citrate in the different tissues as determined by GC-MS analysis.
(C) High-resolution 13C NMR spectra showing 13C enrichment of carboxylic groups in tumor extracts of a [1-13C1]glutamine-infused mouse when compared to a
control mouse.
(D) NMR analysis of 13C enrichment in tumor citrate during the time course of infusion determined by deconvolution of the carboxyl group signals. The area of
the citrate signal was divided by tumor weight and normalized to the dioxane signal. Error bars represent SEM of n = 3.
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In Vivo
VHL-deficient RCC cells rely on RC for lipid synthesis, potentially
suggesting that this reaction can contribute to tumor growth.
Reductive carboxylation is known to occur in bacteria and has
been described in brown adipose tissue (Yoo et al., 2004) but
whether it occurs in vivo in other tissues of vertebrates or in
actual tumors is not known. We sought to determine the activity
of RC in tumors derived from VHL-deficient UMRC3 cells380 Cell Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc.growing as subcutaneous xenografts in nude mice. We infused
several tumor-bearing mice with [1-13C1]glutamine (see Experi-
mental Procedures) and analyzed the citrate enrichment in tumor
extracts by high-resolution 13C nuclear magnetic resonance
(NMR) spectroscopy and GC-MS (Figure 6). [1-13C1]glutamine
will transfer carbon to citrate only through RC, so the mere
detection of 13C enrichment in citrate will indicate that this reac-
tion is active in vivo. In order to attain maximal 13C enrich-
ment of citrate, we carried out a time course infusion of
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13C
glutamine enrichment in the tumor (Figure 6A). We also analyzed
the 13C glutamine enrichment in the plasma at the earliest and
latest infusion points and observed similar 13C enrichment after
6 hr. As seen in Figure 6B, we detected 13C enriched citrate in
the tumor within 30 min, with RC accounting for 4% of citrate
production after 6 hr of infusion (Figure 6B). Notably, the
steady-state 13C glutamine enrichment in the tumor was 30%
(Figure 6A), indicating that the reductive flux accounts for at least
12% of citrate production in VHL-deficient tumors under these
experimental conditions. The kidney cortex is reported to be
relatively hypoxic (Zhong et al., 1998). Thus, we analyzed the
13C citrate enrichment in kidney extracts in parallel and showed
that RC is also active in this organ (Figure 6B). The steady-state
13C enrichment of glutamine was also established in the normal
kidney, but it was higher (Figure 6B), indicating an overall lower
contribution of RC in the kidney when compared to the tumor.
Despite the steady-state 13C enrichment of the glutamine
precursor, the percentage of M1 citrate appeared to increase
overtime in the tumor, whereas it reached a plateau in the normal
kidneys and plasma. Importantly, there was no evidence that RC
appears in the tumor in a delayed fashion compared to plasma or
kidney, strongly suggesting that RC occurs in the tumor xeno-
grafts. Concordant results were obtained by 13C NMR spectros-
copy (Figures 6C and 6D) in which 13C enrichment was observed
in tumor extracts after 6 hr of infusion, and no signal was
detected in the carboxyl group region in control mice (Figure 6C).
These results indicate that RC occurs in vivo, at least in VHL-
deficient tumors.
Loss of VHL Renders RCC Cells Sensitive to Glutamine
Deprivation
RCC cells engaged in RC from glutamine to produce citrate, and
this reaction was active in VHL-deficient RCC xenograft tumors.
We therefore hypothesized that VHL deficiency results in cell
addiction to glutamine for proliferation. We treated the isogenic
clones PRC3 (VHL-deficient cells) and WT8 (VHL-reconstituted
cells) with the glutaminase inhibitor 968 (Wang et al., 2010a).
VHL-deficient PRC3 cells were more sensitive to treatment
with 968, compared to the VHL-reconstituted WT8 cells (Fig-
ure 7A). To confirm that this is not only a cell-line-specific
phenomenon, we also cultured UMRC2 cells in the presence of
968 or diluent control and showed selective sensitivity of VHL-
deficient cells (Figure 7B). To test if the selective sensitivity of
VHL-deficient cells to glutaminase inhibitors is linked, at least
in part, to defective carbon supply, we asked whether cell prolif-
eration could be rescued by anaplerotic substrates. Supple-
menting the cultured medium with a cell-permeable form of the
substrate a-ketoglutarate or acetate, we rescued VHL-deficient
cells from treatmentwith 968 (Figure 7C). The selective sensitivity
and rescue by anaplerotic and lipogenic substrates was also
corroborated in 786-O cells (Figure 7D). We observed a similar
growth-inhibitory phenotype inVHL-deficient UMRC2 cells using
a different glutaminase inhibitor (BPTES), confirming the sensi-
tivity to glutamine deprivation under VHL-deficient conditions
(Figure 7E). Glutamine addiction of VHL-deficient cells is not an
in-vitro-only phenomenon. Systemic administration of the gluta-
minase inhibitor BPTES suppressed the growth of VHL-deficient
UMRC3 cells as tumors in nude mice (Figure 7F).CeIn summary, our findings show that HIF is necessary and suffi-
cient to promote RC from glutamine. By inhibiting glucose oxida-
tion in the TCA cycle and reducing citrate levels, HIF shifts the
IDH reaction toward RC to support citrate production and lipo-
genesis (Figure 7G). The reductive flux is active in vivo, fuels
tumor growth, and can potentially be targeted pharmacologi-
cally. Understanding the significance of reductive glutamine
metabolism in tumors may lead to metabolism-based thera-
peutic strategies.
DISCUSSION
Along with others, we reported that hypoxia and loss of VHL
engage cells in reductive carboxylation (RC) from glutamine
to support citrate and lipid synthesis (Filipp et al., 2012; Metallo
et al., 2012; Wise et al., 2011). Wise et al. (2011) suggested that
inactivation of HIF in VHL-deficient cells leads to reduction of
RC. These observations raise the hypothesis that HIF, which
is induced by hypoxia and is constitutively active in VHL-
deficient cells, mediates RC. In our current work, we provide
mechanistic insights that link HIF to RC. First, we demonstrate
that polyclonal reconstitution of VHL in several human VHL-
deficient RCC cell lines inhibits RC and restores glucose
oxidation. Second, the VHL mutational analysis demonstrates
that the ability of pVHL to mitigate reductive lipogenesis is
mediated by HIF and is not the outcome of previously reported,
HIF-independent pVHL function(s). Third, to prove our hypoth-
esis we showed that constitutive expression of a VHL-indepen-
dent HIF mutant is sufficient to phenocopy the reductive
phenotype observed in VHL-deficient cells. In addition, we
showed that RC is not a mere in vitro phenomenon, but it
can be detected in vivo in human tumors growing as mouse
xenografts. Lastly, treatment of VHL-deficient human xeno-
grafts with glutaminase inhibitors led to suppression of their
growth as tumors.
In this work, we also examined themechanism(s) by which HIF
promotes RC. It is established that hypoxic induction of HIF
transactivates several enzymes involved in glucose uptake and
glycolysis, including GLUT1, hexokinase, phosphofructokinase,
and aldolase (Iyer et al., 1998). In addition, HIF directly binds to
the promoter of, and transactivates, PKM2, pyruvate dehydro-
genase kinase 1 (PDK1) and lactate dehydrogenase A (LDHA)
(Ebert et al., 1996; Firth et al., 1994; Kim et al., 2006; Luo et al.,
2011; Papandreou et al., 2006). This orchestrated upregulation
of several enzymes ensures the diversion of pyruvate to lactate
production. This raises the hypothesis that RC may be triggered
by a deficient pyruvate oxidation in the mitochondrion and the
subsequent reduction in citrate levels. Our MFA analysis indi-
cated a significantly lower absolute pyruvate dehydrogenase
(PDH) flux and net conversion of a-ketoglutarate into citrate
upon HIF activation. The ATP citrate lyase flux was lower in
VHL-deficient cells when compared to the VHL-positive counter-
parts, which supports our previous observations that de novo
lipogenesis is decreased under hypoxia conditions (Metallo
et al., 2012). Indeed, HIF expression, either by loss of VHL or
normoxic induction of HIF-2a P-A, reduced citrate levels.
Conversely, administration of exogenous citrate or acetate in
VHL-deficient cells restored the low citrate levels to the levels
encountered in VHL-replete cells and inhibited RC. Exogenousll Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc. 381
Figure 7. VHL-Deficient Cells and Tumors Are Sensitive to Glutamine Deprivation
(A–E) Cell proliferation is normalized to the corresponding cell type grown in 1 mM glutamine-containing medium. Effect of treatment with glutaminase (GLS)
inhibitor 968 in PRC3/WT8 (A) and UMRC2 cells (B). Rescue of GLS inhibition with dimethyl alpha-ketoglutarate (DM-Akg; 4 mM) or acetate (4 mM) in PRC3/WT8
clonal cells (C) and polyclonal 786-O cells (D). Effect of GLS inhibitor BPTES in UMRC2 cells (E). Student’s t test compares VHL-reconstituted cells to control cells
in (A), (B), and (E) and DM-Akg or acetate-rescued cells to correspondent control cells treated with 968 only in (C) and (D) (asterisk in parenthesis indicates
comparison between VHL-reconstituted to control cells). Error bars represent SEM.
(F) GLS inhibitor BPTES suppresses growth of human UMRC3 RCC cells as xenografts in nu/nu mice. When the tumors reached 100mm3, injections with BPTES
or vehicle control were carried out daily for 14 days (n = 12). BPTES treatment decreases tumor size and mass (see insert). Student’s t test compares control to
BPTES-treated mice (F). Error bars represent SEM.
(G) Diagram showing the regulation of reductive carboxylation by HIF.
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VHL-positive cells. In the case of either cell type, the magnitude
of changes in RC reflected the degree of changes in intracellular
citrate levels. These observations show that fluctuations in
citrate levels by HIF modulate, at least in part, the flux of the
reverse IDH reaction. This finding underlines the compensatory
role of RC in maintaining an adequate flux for lipogenesis under
HIF-activated conditions.
In addition to the role of HIF in regulating RC through citrate,
we examined whether HIF directly regulates enzymes along the
reductive TCA cycle pathway (see Figure 1B). We did not
observe changes in the transcript or protein levels of GLS,
GDH, IDH1, IDH2, ACO1, or ATP citrate lyase between VHL-
deficient and VHL-reconstituted UMRC2 cells. This is in line
with previous studies that did not identify any of these enzymes
as transcriptional targets of HIF-1a or HIF-2a (Mole et al., 2009;
Ortiz-Barahona et al., 2010; Scho¨del et al., 2011; Wenger et al.,
2005). Nevertheless, it is conceivable that HIF may affect the
activity of these enzymes through regulation of cofactor avail-
ability or posttranslational modification of the enzymes. For
example, the reverse IDH reaction requires NADPH, as allo-
steric cofactor (Dalziel and Londesborough, 1968; Leonardi
et al., 2012) and HIF-mediated changes in NADPH levels may
indirectly influence IDH activity. In our studies we did not
observe increased NADPH levels in VHL-deficient cells when
compared to the VHL-positive counterparts, which is in agree-
ment with existing literature showing that HIF-1a activates
NADPH oxidase and hypoxia limits NADPH production
(Diebold et al., 2010; Tribble and Jones, 1990). These data
suggest that the mass-action effect of HIF toward RC is not
accounted for by an increase in NADPH production. Other
signaling pathways may regulate RC through NADPH avail-
ability, and the source(s) of NADPH contributing to RC in the
cytosol/mitochondrion are under investigation. For example,
the mitochondrial enzyme nicotinamide nucleotide transhy-
drogenase (NNT) transfers reducing equivalents from NADH
to NADPH and has been hypothesized to contribute to RC
by IDH2 (Sazanov and Jackson, 1994). This hypothesis,
although not yet experimentally tested, raises the possibility
that NADPH-producing reactions may regulate the RC flux in
a HIF-independent manner.
In addition, posttranslational modifications of the enzymes
involved in RC may be influenced by hypoxia and/or HIF ex-
pression indirectly. For example, aconitase (ACO1) activity is
reportedly regulated by hypoxia through iron-sulfur cluster modi-
fications and phosphorylation (Chan et al., 2009; Rouault, 2006),
and acetyl-CoA is a required substrate for protein acetylation,
which regulates major cellular functions including central carbon
metabolism (Wang et al., 2010b; Zhao et al., 2010). Thus, it
is conceivable that HIF contributes to these modifications and
therefore influences the activity of glutamine-metabolizing
enzymes at the posttranslational level.
Our current work showed that HIF-2a is sufficient to induce the
reductive program in RCC cells that express only the HIF-2a
paralog, while mouse NEK cells appeared to use HIF-1a prefer-
entially to promote RC. Together with the evidence that HIF-1a
and HIF-2a may have opposite roles in tumor growth (Keith
et al., 2011; Maranchie et al., 2002; Raval et al., 2005), it is
possible that the cellular context dictates which paralog acti-Cevates RC. It is also possible that HIF-2a adopts the RC
regulatory function of HIF-1a upon deletion of the latter in RCC
cells. Further studies are warranted in understanding the re-
lative role of HIF-a paralogs in regulating RC in different cell
types.
Finally, the selective sensitivity to glutaminase inhibitors ex-
hibited by VHL-deficient cells, together with the observed RC
activity in vivo, strongly suggests that reductive glutamine
metabolism may fuel tumor growth. Investigating whether the
reductive flux correlates with tumor hypoxia and/or contributes
to the actual cell survival under low oxygen conditions is
warranted. Together, our findings underscore the biological
significance of reductive carboxylation in VHL-deficient RCC
cells. Targeting this metabolic signature of HIF may open viable
therapeutic opportunities for the treatment of hypoxic and VHL-
deficient tumors.
EXPERIMENTAL PROCEDURES
Cell Culture and Metabolic Labeling
All cell lines were obtained from ATCC, tested for mycoplasma, and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-BRL) con-
taining 10% FBS (HyClone) supplemented with penicillin-streptomycin
(Invitrogen). Metabolic labeling was described before (Metallo et al., 2012).
Cellular Metabolite Extractions and GC-MS Analysis
The method was described before (Metallo et al., 2012). Briefly, metabolic
activity was quenched with methanol (80C), an equal volume of water
was added, and cells were collected in tubes by pipette scraping the wells.
Two volumes of chloroform (20C) were added to each tube, extracts were
vortexed and centrifuged at 11,000 RPM for 10min at 4C. The aqueous phase
was used for polar metabolite analysis, and the chloroform phase was used for
fatty acid analysis. Polar phase containing amino and organic acids was evap-
orated, dissolved in 2% methoxyamine hydrochloride in pyridine, derivatized
by adding N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide + 1% tert-
butyldimethylchlorosilane, and subjected to GC-MS analysis. Fatty acid
methyl esters (FAMEs) were obtained by reacting the nonpolar phase with
2%H2SO4:methanol. After transesterification, FAMEs were isolated by adding
hexane and saturated NaCl. The hexane phase was subjected to GC-MS
analysis.
Metabolic Flux Analysis and Isotopomer Spectral Analysis
Intracellular fluxes and the specific contribution to lipogenic acetyl-CoA were
estimated using the elementary metabolite unit (EMU) framework-based
software Metran, executed in Matlab (Mathworks) as previously described
(Metallo et al., 2012).
Metabolite Analysis of Extracellular Medium
Cells were seeded at low density in basal DMEM and the spent medium was
collected at the end of a 72 hr growth period and analyzed using a Yellow
Springs Instruments (YSI) 7100.
Determination of NADP+/NADPH Ratios
Cellular NADP+/NADPH levels were assayed using a fluorescence-based
assay according to the manufacturer’s instructions (Cell Technology).
NADP+/NADPH ratios were also determined employing themethod developed
in the Krebs lab, as described therein (Veech et al., 1969).
Plasmids and Western Blots
Plasmids expressing HA-VHL mutants and HA-HIF-2a were purchased from
Addgene. Plasmids encoding shRNA sequences targeting PDK1 and ACLY
were obtained from the Broad Institute RNAi Consortium (TRC) library
available at Massachusetts General Hostpital (MGH) (shRNA sequences
available in the Supplemental Experimental Procedures). Proteins were ex-
tracted and immunobloted as described before (Zimmer et al., 2008).ll Metabolism 17, 372–385, March 5, 2013 ª2013 Elsevier Inc. 383
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All protocols conformed to institutional regulations. UMRC3 cells were injected
subcutaneously in nu/nu mice (5 3 106 cells per injection). Tumor volumes
were calculated as length (mm) 3 width2 (mm2)3 0.5. For in vivo 13C-labeling
studies, animals (n = 3) were infused with [1-13C1]glutamine for the indicated
time periods as previously described (Marin-Valencia et al., 2012).
13C NMR Spectroscopy
High-resolution proton-decoupled 13C NMR spectra of tumor extracts were
obtained at 11.7 T (125.13 Hz, 25C [pH 7.2]) in a Bruker AVANCE III 500
MHz Wide Bore NMR spectrometer using a commercial (5 mm) triple-
resonance probe (1H, 13C, 2H) optimized for direct 13C detection.
Statistical Analysis
For MFA and ISA results, error bars represent 95% confidence intervals. In
all other experiments, error bars represent SEM unless otherwise noted.
Statistical significance was determined using two-tailed Student’s t test.
*p < 0.05, **p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2013.02.002.
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